Company research
AURORA CANNABIS INC
CIK 1683541Updated Nov 10, 2026
SecuritiesACB · NASDAQ · equityACB · TSX · equity
Historical securities (2)
ACBFF · OTC · equity · closed Oct 23, 2018ACBWF · OTC · warrant · closed Apr 27, 2023ACB price & chart
Loading TradingView…
NASDAQ:ACB on TradingView ↗About the company
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · CADSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCAD | 1,591,000Source | -69,326,000Source | -1,717,979,000Source | -695,089,000Source |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsCAD | 11,524,000Source | 12,717,000Source | 13,757,000Source | 20,243,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -11,453,000Source | 105,000Source | -1,915,000Source | 3,420,000Source |
| GeneralAndAdministrativeExpenseCAD | 97,257,000Source | 92,222,000Source | 113,212,000Source | 119,437,000Source |
| GoodwillCAD | 43,871,000Source | 43,180,000Source | 0Source | 887,737,000Source |
| IncreaseDecreaseInWorkingCapitalCAD | -10,210,000Source | 15,627,000Source | -52,652,000Source | -397,000Source |
| InterestPaidClassifiedAsOperatingActivitiesCAD | 6,844,000Source | 11,700,000Source | 27,725,000Source | 34,157,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 5,240,000Source | 5,627,000Source | 7,545,000Source | 5,416,000Source |
| ProceedsFromIssuingSharesCAD | 0Source | 37,926,000Source | 350,188,000Source | 666,026,000Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodCAD | 5,488,000Source | 4,993,000Source | 0Source | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCAD | — | — | 19,648,000Source | 19,241,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesCAD | 7,245,000Source | 3,042,000Source | 0Source | — |
income statement · annual statements
| Line item | Q4 2022 | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseCAD | — | — | 144,159,000Source | 175,237,000Source | — |
| Total RevenueCAD | — | — | — | 221,339,000Source | 245,252,000Source |
| Additional Financial Items | |||||
| ApplicableTaxRatenumber | — | 0.27Source | 0.27Source | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareCAD/shares | — | 0.04Source | -1.52Source | -7.99Source | — |
| CurrentTaxExpenseIncomeCAD | — | 7,808,000Source | 1,109,000Source | 52,000Source | 122,000Source |
| DeferredTaxExpenseIncomeCAD | — | -3,189,000Source | -1,663,000Source | -2,193,000Source | -6,443,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossCAD | — | — | — | — | -6,542,000Source |
| DepreciationAndAmortisationExpenseCAD | — | 9,080,000Source | 12,139,000Source | 48,602,000Source | 49,174,000Source |
| DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssetsCAD | — | 27,445,000Source | — | — | — |
| DilutedEarningsLossPerShareCAD/shares | — | 0.04Source | -1.52Source | -7.99Source | — |
| FinanceCostsCAD | — | 8,420,000Source | 14,186,000Source | 71,813,000Source | 66,437,000Source |
| GainsLossesRecognisedWhenControlInSubsidiaryIsLostCAD | — | — | 0Source | 0Source | 0Source |
| GeneralAndAdministrativeExpenseCAD | — | 97,257,000Source | 92,222,000Source | 113,212,000Source | 119,437,000Source |
| GrossProfitCAD | — | 187,607,000Source | 131,460,000Source | 21,225,000Source | -21,558,000Source |
| ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentIncludingRightofuseAssetsCAD | — | 696,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsCAD | — | 4,619,000Source | -554,000Source | -2,141,000Source | -6,321,000Source |
| InterestExpenseOnLeaseLiabilitiesCAD | — | 2,921,000Source | 3,152,000Source | 3,433,000Source | 4,597,000Source |
| ProfitLossAttributableToNoncontrollingInterestsCAD | — | — | — | -355,000Source | — |
| ProfitLossAttributableToOwnersOfParentCAD | — | — | — | -1,717,624,000Source | — |
| ProfitLossBeforeTaxCAD | — | 20,382,000Source | -59,599,000Source | -1,720,120,000Source | -699,798,000Source |
| ProfitLossFromOperatingActivitiesCAD | — | 4,948,000Source | -46,453,000Source | -231,449,000Source | -282,818,000Source |
| ResearchAndDevelopmentExpenseCAD | — | 3,676,000Source | 3,572,000Source | 10,389,000Source | 11,447,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodCAD | — | — | — | 293,000Source | 509,000Source |
Filing attachments
tm2629252d1_ex99-1.htm · 6-K · 2026-11-09
Exhibit 99.1 Date: November 9, 2026 510 Burrard Street, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com ───────────────────────────────────────────────────────────────────────────────────── To: All Canadian Securities Regulatory Authorities Subject: AURORA CANNABIS INC. Dea…
Read attachment ↗tm2629080d1_ex99-1.htm · 6-K · 2026-11-05
Exhibit 99.1 November 5, 2026 NASDAQ | TSX: ACB ──────────────────────────────────── Aurora Cannabis Announces Fiscal 2027 Second Quarter Results Delivers Net Revenue of $86.0 million, including Record International Medical Cannabis Net Revenue of $61.4 million, representing a 44% YoY Increase Generated Adjusted EBITDA1 of $14.0 million, with Free Cash Flow1 Outflow Improving by $22.4 million Maintains Strong Balance Sheet with $133.0 million of Cash,…
Read attachment ↗tm2628851d1_ex99-1.htm · 6-K · 2026-11-04
Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Name and Address of Company: ──────────────────────────────── Aurora Cannabis Inc. (“Aurora” or the “Company”) 2207-90B Street SW Edmonton, Alberta T6X 1V8 Date of Material Change: ──────────────────────────── November 2, 2026 News Release: A press release describing the material change was disseminated by Aurora on November 3, 2026 through Business Wire and can be found on SEDAR+ at www.sedarplus.ca. Summary of Material Cha…
Read attachment ↗tm2628851d1_ex99-2.htm · 6-K · 2026-11-04
Exhibit 99.2 SEDAR+ Version ORGANIGRAM GLOBAL INC. - and - AURORA CANNABIS INC. ARRANGEMENT AGREEMENT November 2, 2026 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 2 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Page …
Read attachment ↗tm2628773d2_ex99-1.htm · 6-K · 2026-11-03
Exhibit 99.1 Organigram to Acquire Aurora and Establish a Global Cannabis Leader Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration. Transaction provides Aurora shareholders with certainty of value, meaningful immediate liquidity and participation in the combined entity Offer represents a 93% premium to Aurora’s Unaffected Sha…
Read attachment ↗tm2628516d1_ex99-1.htm · 6-K · 2026-10-29
Exhibit 99.1 October 29, 2026 NASDAQ | TSX: ACB ─────────────────────────────────────────── Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call Edmonton, AB - October 29, 2026 - Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its…
Read attachment ↗